bio-logical zinc solution
orthomolecular medisearch laboratories pty ltd trading as biological therapies - zinc sulfate heptahydrate -
csnz spf50+ invisible protect zinc
baxter laboratories pty ltd - zinc oxide -
cissy natural zinc sunscreen lotion spf30
baxter laboratories pty ltd - zinc oxide -
cs mineral zinc spf30+ sunscreen
baxter laboratories pty ltd - zinc oxide -
sett surf spf30 wr zinc lotion
baxter laboratories pty ltd - zinc oxide -
life coli 10%w/w premix powder
life biopharma sdn. bhd. - colistin sulphate -
ascazin capsules (zinc 50.96mg)
unimed sdn bhd - zinc sulphate monohydrate. -
life linco-spec premix
life biopharma sdn. bhd. - lincomycin hydrochloride (monohydrate); spectinomycin sulfate (tetrahydrate) -
folinz tablets
apex laboratories private limited sidco garment complex iii floor,guindy 600032, - zinc sulfate and folic acid tablets - tablet - folic acid bp 5mg zinc sulfate monohydrate usp - antianemic preparations - vitamin b12 and folic
kepivance- palifermin injection, powder, lyophilized, for solution
swedish orphan biovitrum ab (publ) - palifermin (unii: qms40680k6) (palifermin - unii:qms40680k6) - palifermin 6.25 mg in 1.2 ml - kepivance is indicated to decrease the incidence and duration of severe oral mucositis in patients with hematologic malignancies receiving myelotoxic therapy in the setting of autologous hematopoietic stem cell support. kepivance is indicated as supportive care for preparative regimens predicted to result in ≥ who grade 3 mucositis in the majority of patients. kepivance is a mucocutaneous epithelial human growth factor indicated to decrease the incidence and duration of severe oral mucositis in patients with hematologic malignancies receiving myelotoxic therapy in the setting of autologous hematopoietic stem cell support. kepivance is indicated as supportive care for preparative regimens predicted to result in ≥ who grade 3 mucositis in the majority of patients. the safety and efficacy of kepivance have not been established in patients with non-hematologic malignancies )]. the safety and efficacy of kepivance have not been established in patients with non-hematologic malignancies